NCT05075564 - A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions

Advanced Solid Tumor

Interventions

DRUG

Part 1 ES002023

ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

DRUG

Part 2 ES002023

ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Trial Locations (7)

22031

NEXT Virginia, Fairfax

32827

Sarah Cannon Research Institute, Orlando

72703

Fayetteville Oncology, Fayetteville

78758

NEXT Austin, Austin

85258

HonorHealth, Scottsdale

90095

UCLA, Los Angeles

08901

Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

Elpiscience Biopharma, Ltd.

INDUSTRY